- Home
- VKTX vs ICUI Comparison
VKTX vs ICUI Comparison
Compare VKTX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- ICUI
- Stock Information
- Founded
- VKTX 2012
- ICUI 1984
- Country
- VKTX United States
- ICUI United States
- Employees
- VKTX N/A
- ICUI N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- ICUI Medical/Dental Instruments
- Sector
- VKTX Health Care
- ICUI Health Care
- Exchange
- VKTX Nasdaq
- ICUI Nasdaq
- Market Cap
- VKTX 3.4B
- ICUI 3.6B
- IPO Year
- VKTX 2015
- ICUI 1992
- Fundamental
- Price
- VKTX $23.91
- ICUI $137.80
- Analyst Decision
- VKTX Strong Buy
- ICUI Buy
- Analyst Count
- VKTX 11
- ICUI 4
- Target Price
- VKTX $95.18
- ICUI $199.67
- AVG Volume (30 Days)
- VKTX 3.8M
- ICUI 292.2K
- Earning Date
- VKTX 04-23-2025
- ICUI 05-06-2025
- Dividend Yield
- VKTX N/A
- ICUI N/A
- EPS Growth
- VKTX N/A
- ICUI N/A
- EPS
- VKTX N/A
- ICUI N/A
- Revenue
- VKTX N/A
- ICUI $2,382,046,000.00
- Revenue This Year
- VKTX N/A
- ICUI $0.67
- Revenue Next Year
- VKTX N/A
- ICUI $3.42
- P/E Ratio
- VKTX N/A
- ICUI N/A
- Revenue Growth
- VKTX N/A
- ICUI 5.44
- 52 Week Low
- VKTX $23.27
- ICUI $93.36
- 52 Week High
- VKTX $81.86
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- VKTX 33.36
- ICUI 37.30
- Support Level
- VKTX $23.27
- ICUI $135.42
- Resistance Level
- VKTX $29.60
- ICUI $152.06
- Average True Range (ATR)
- VKTX 1.52
- ICUI 5.51
- MACD
- VKTX -0.38
- ICUI -0.30
- Stochastic Oscillator
- VKTX 7.80
- ICUI 13.49
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.